Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,686
Out of 5,124 analysts
11
Total ratings
10%
Success rate
-30.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $4.16 | +476.92% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $0.89 | +570.47% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.80 | +292.86% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $8.86 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.19 | +1,315.53% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.88 | +128.43% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $0.92 | +1,421.57% | 1 | Aug 15, 2025 |
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $4.16
Upside: +476.92%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $0.89
Upside: +570.47%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.80
Upside: +292.86%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.86
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.19
Upside: +1,315.53%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.88
Upside: +128.43%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $0.92
Upside: +1,421.57%